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The increasing prescription of opioids is fueling an epidemic of addiction and overdose
deaths. Morphine is a highly addictive drug characterized by a high relapse rate – even
after a long period of abstinence. Serotonin (5-HT) neurotransmission participates in
the development of morphine dependence, as well as the expression of morphine
withdrawal. In this study, we examined the effect of blockade of 5-HT2A receptors
(5-HT2ARs) on morphine-induced behavioral sensitization and withdrawal in male
mice. 5-HT2AR antagonist MDL 11,939 (0.5 mg/kg, i.p.) suppressed acute morphine
(5.0 mg/kg, s.c.)-induced increase in locomotor activity. Mice received morphine
(10 mg/kg, s.c.) twice a day for 3 days and then drug treatment was suspended for
5 days. On day 9, a challenge dose of morphine (10 mg/kg) was administered to induce
the expression of behavioral sensitization. MDL 11,939 (0.5 mg/kg, i.p.) pretreatment
suppressed the expression of morphine-induced behavioral sensitization. Another
cohort of mice received increasing doses of morphine over a 7-day period to induce
morphine-dependence. MDL 11,939 (0.5 mg/kg, i.p.) prevented naloxone-precipitated
withdrawal in morphine-dependent mice on day 7. Moreover, chronic morphine
treatment increased 5-HT2AR protein level and decreased the phosphorylation of
extracellular signal-regulated kinases in the prefrontal cortex. Together, these results by
the first time demonstrate that 5-HT2ARs modulate opioid dependence and blockade
of 5-HT2AR may represent a novel strategy for the treatment of morphine use
disorders.
Highlights
(i) Blockade of 5-HT2A receptors suppresses the expression of morphine-induced
behavioral sensitization.
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(ii) Blockade of 5-HT2A receptors suppresses naloxone-precipitated withdrawal in
morphine-treated mice.
(iii) Chronic morphine exposure induces an increase in 5-HT2A receptor protein level and
a decrease in ERK protein phosphorylation in prefrontal cortex.
Keywords: serotonin, 5-HT2A receptor, morphine, behavioral sensitization, withdrawal, prefrontal cortex,
hippocampus
INTRODUCTION
Morphine and other prescription opioids are the mainstay
clinical treatment for moderate to severe acute pain. The
increasing prescription of opioids is fueling an epidemic of
addiction and overdose deaths (Volkow et al., 2014). In addition,
there has been an alarming rise in the illegal use of opioids
in the United States over the past two decades (Varrassi and
Muller-Schwefe, 2012). Morphine is a highly addictive opioid and
the rate of relapse is remarkably high – even after long periods
of abstinence (Blondell et al., 2013). The neural mechanisms
underlying morphine addiction and relapse remain elusive
(Volkow et al., 2014).
Serotonergic fibers originate from raphe nuclei and distribute
across the brain, including the prefrontal cortex (PFC) and
ventral tegmental area (VTA). Besides its well-documented
regulation of sensory perception, mood and cognition, serotonin
(5-HT) neurotransmission in the brain affects the development
of morphine dependence and the expression of morphine
withdrawal (el-Kadi and Sharif, 1995; Muller and Homberg,
2015). There are seven 5-HT receptor families (5-HT1−7),
encompassing 14 receptor subtypes together with a variety of
splice variants (Hannon and Hoyer, 2008). 5-HT2A receptor
(5-HT2AR) is a G protein-coupled receptor (GPCR) of the
type A family. 5-HT2ARs are widely distributed across the
central nervous system. 5-HT2ARs regulate cellular function
via G protein-dependent, ligand-dependent and ligand-
independent signaling pathways, including phospholipase
signaling, extracellular signal-regulated kinases (ERK) pathway
and tyrosine kinase pathway in neural tissues (Millan et al.,
2008; Masson et al., 2012). Pharmacological blockade of 5-
HT2ARs presents antipsychotic and antidepressant properties,
however, receptor activation possesses cognition enhancement
and hallucinogenic properties (Zhang and Stackman, 2015).
Accumulating evidence indicates that the 5-HT2AR is involved
in the behavioral changes elicited by psychostimulants and
drugs of abuse. 5-HT2AR antagonist M100907 suppressed
behavioral hyperactivity induced by cocaine (Fletcher
et al., 2002), MK-801, amphetamine (O’Neill et al., 1999)
and morphine (Auclair et al., 2004). In addition, M100907
attenuated cocaine priming or cocaine associated cue induced
reinstatement of drug-seeking behaviors in rats (Fletcher et al.,
2002; Nic Dhonnchadha et al., 2009), and inhibited nicotine
priming or nicotine-associated cue induced reinstatement
(Fletcher et al., 2012) and nicotine sensitization (Zaniewska
et al., 2010). To date, there is little if any reports of the
modulation of 5-HT2ARs on morphine-induced behavioral
changes.
Chronic opioid treatment can induce a behavioral
sensitization, a key factor critical for the acquisition and
maintenance of compulsive drug-seeking behavior. The
behavioral sensitization may reflect the neuroplasticity associated
with addictive drug exposure that causes hyperactivity of neurons
that innervate the NAc, such as dopaminergic neurons in VTA,
glutamatergic neurons in PFC and basolateral amygdala (BLA;
Kalivas and Stewart, 1991). Physical dependence or withdrawal
also play a critical role in the reinstatement of drug-seeking
behaviors (Robinson and Berridge, 1993). In the present study
we investigated the effect of 5-HT2AR blockade with MDL
11,939, a potent and selective antagonist for 5-HT2AR (Ki values
are 0.54 and 2.5 nM at rabbit 5-HT2AR and human 5-HT2AR,
respectively), on morphine-induced behavioral sensitization
and withdrawal symptoms and further explored the effect of
chronic morphine treatment on 5-HT2AR protein level and ERK
phosphorylation in mice. Glemanserin (MDL 11,939) has been
investigated clinically for the treatment of generalized anxiety
disorder (Sramek et al., 1995). Our data revealed that MDL
11,939 suppressed morphine-induced increase in locomotor
activity, behavioral sensitization and withdrawal symptoms in
male mice.
MATERIALS AND METHODS
Animals
Adult male Kunming mice at 22 ± 2 gram came from the
Experimental Animal Center of Anhui Medical University (Hefei,
China) and housed in groups of four per cage with ad libitum
access to food and water. Mouse cages were maintained in a
temperature and humidity controlled vivarium with 12/12 h
light/dark cycle (lights on at 7:00 am) for at least 1 week prior to
experiments. All procedures conducted were in accordance with
the guidelines in the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committee at Anhui Medical
University.
Chemicals and Reagents
Morphine hydrochloride was purchased from The First
Pharmaceutical Co. Ltd of Shenyang (Shenyang, China),
naloxone hydrochloride was obtained from Kangze
Pharmaceutical Co. Ltd (Hunan, China), and MDL 11,939
was purchased from Tocris Bioscience (Minneapolis, MN, USA).
MDL 11,939 was dissolved in sterile saline containing 1% DMSO,
and all other compounds were dissolved in 0.9% sterile normal
saline. The drug concentrations were adjusted to an injection
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volume of 10 ml/kg body weight. The 5-HT2AR primary
antibody was purchased from Abcam (ab16028, Cambridge, MA,
USA). Primary antibodies to (phospho-) ERK1/2 came from
Bioworld Technology Inc. (Nanjing, China). The secondary
HRP-conjugated anti-mouse IgG antibody for the Western
blot (WB) assay came from Beijing Zhong-Shan Biotechnology
Co., Ltd (Beijing, China). Enhanced Bicinchoninic acid (BCA)
protein assay kit came from Beyotim Institute of Biotechnology
(Haimen, China).
Morphine-Induced Behavioral
Sensitization
The morphine-induced behavioral sensitization mouse model
was developed based on our previous publication (Zhang et al.,
2016b). In brief, mice received morphine (10 mg/kg, s.c.) twice
a day (8:00 am and 7:00 pm) for 3 days and then morphine
injection was suspended for 5 days. On day 9, a challenge dose
of morphine (10 mg/kg, s.c.) was given and the locomotor
activity was recorded immediately for 1 h (Li et al., 2008). To
examine whether 5-HT2ARs affect the expression of behavioral
sensitization, MDL 11,939 (0.5 mg/kg, i.p.) was administered
20 min prior to morphine challenge on day 9 to examine
behavioral changes.
Induction of Morphine Dependence and
Withdrawal
The morphine-induced dependence and withdrawal mouse
model was developed based on our previous publication (Zhang
et al., 2016b). In brief, mice received morphine three times per
day starting at a dose of 5 mg/kg (s.c.) and the dose was increased
each day until reaching 100 mg/kg by day 6. On day 7, morphine
(100 mg/kg, s.c.) was administered at 8:00 am and 2:00 pm.
2.5 h later, the mice received vehicle or MDL 11,939 (0.5 mg/kg,
i.p.) treatment followed by naloxone challenge (5.0 mg/kg, i.p.)
15 min later to precipitate morphine withdrawal symptoms.
Mice were placed individually into square observation chambers
(30 cm × 30 cm × 35 cm tall) and closely observed for 30 min
immediately after naloxone challenge.
Open Field Test and Behavioral
Assessment
Horizontal distance traveled and other behavioral phenotypes
were tracked with EthoVision XT 5.1 PhenoTyper system
(Noldus Information Technology, Wageningen, The
Netherlands). The EthoVision software detected the mouse in
static subtraction mode (a white mouse on a black background)
in each video frame (29.97 fps) and tracked the movement of the
digitized pixels that represent the “center point” of the mouse.
Distance traveled and immobility were used to assess locomotor
activity. A mouse that reared or was grooming would not be
detected as immobile (Wu et al., 2015; Zhang et al., 2016b). The
withdrawal symptoms quantified included jumping (all feet off
the floor), burrowing (escape digging), body grooming, rearing
(front feet off the floor), wet dog shakes (whole body shakes), and
other behaviors for 30 min (Wu et al., 2015; Zhang et al., 2016b).
Western Blot
Brains from the mice receiving the escalating morphine
treatment were rapidly harvested on day 7 and then stored
at −80◦C before processing for 5-HT2AR WB. The selected
brain regions from two mice were pooled together to obtain a
sufficient amount of protein necessary for perform WB analysis.
Tissue samples obtained from the PFC and hippocampus were
homogenized in ice-cold RIPA lysis buffer before centrifuging at
15,000 × g at 4◦C for 10 min. The supernatant was collected as
total proteins and the protein concentration was examined using
a BCA protein assay kit. Samples containing 30 µg proteins were
separated by 12% SDS-polyacrylamide gel and, then, transferred
to polyvinylidene difluoride (PVDF) membranes. After blocking
with 5% (w/v) non-fat dry milk and washing in Tris-buffered
saline containing 0.1% v/v tween-20 (TBST), the membrane
loaded was incubated with the primary antibody (1:100) at 4◦C
overnight followed by incubation with horseradish peroxidase-
conjugated secondary antibody (goat anti-mouse; 1:10,000).
Protein bands were visualized by an enhanced chemiluminescent
substrate (Thermo Fisher Scientific Inc. Waltham, MA, USA)
and captured by the Bioshine ChemiQ4600 imaging system
(Shanghai Bioshine Scientific instrument Co., Ltd, Shanghai,
China). Densitometry (mean of gray scale) was performed using
ImageJ software (NIH). 5-HT2AR densitometry values were
normalized to corresponding β-actin immunoreactivity in the
same lane to reduce any loading and transfer variances among the
samples (Zhang et al., 2016b). Each group consists of 3–4 trials.
Statistical Analysis
Statistical differences in distance traveled and immobility were
determined by a two-way repeated measures analysis of variance
(ANOVA). If significance was found, a post hoc Bonferroni
multiple comparison test was used to compare the difference
between two groups. Independent samples Student’s t-test was
used to analyze the difference between two groups. All statistical
tests were conducted using the SPSS v19 (IBM, Armonk, NY,
USA) software package. Data were expressed as mean ± S.E.M.
P < 0.05 was considered statistically significant.
RESULTS
MDL 11,939 Suppresses Acute
Morphine-Induced Hyperactivity
Systemic MDL 11,939 (0.5 mg/kg, i.p.) did not affect the
locomotor activity 20 min after injector (Supplementary Figure
S1). Therefore, MDL 11,939 was administered 20 min prior to
morphine (5 mg/kg, s.c.) injection. The locomotor activity was
recorded for 60 min immediately after morphine administration.
MDL 11,939 altered morphine-induced increase in locomotor
activity. A two-way repeated measures ANOVA on distance
traveled measured in 5-min bins revealed a significant main
effect of treatment [F(3,32) = 6.398, p = 0.002] and a
significant main effect of treatment × time bin interaction
[F(33,352) = 2.949, p < 0.001], but no effect of time bin
[F(11,352) = 1.471, p = 0.140] (Figure 1A). Post hoc Bonferroni
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FIGURE 1 | MDL 11,939 suppresses acute morphine-induced hyperactivity. MDL 11,939 (0.5 mg/kg, i.p.) was administered 20 min prior to the injection of
morphine (5 mg/kg, s.c.). Locomotor activity was recorded for 60 min immediately after morphine administration. (A) Morphine-treated mice presented a significant
increase in the distance traveled compared with the control mice (vehicle + morphine vs. vehicle + saline, p = 0.011). MDL11,939 prevented the morphine-induced
increase in locomotor activity (MDL 11,939 + morphine vs. vehicle + saline, p = 1.000). Morphine-treated mice presented an increase in the distance traveled from
20 to 60 min compared with the control mice (vehicle + morphine vs. vehicle + saline). (B) Morphine treatment significantly suppressed immobility compared with
the vehicle (vehicle + morphine vs. vehicle + saline, p = 0.047). MDL11,939 prevented the morphine-induced decrease in immobility (MDL 11,939 + morphine vs.
vehicle + saline, p = 1.000). Morphine-treated mice presented a decrease in immobility from 25 to 45 min compared with the control mice (vehicle + morphine vs.
vehicle + saline). Data are expressed as mean ± S.E.M; n = 9 in each group; ∗p < 0.05, ∗∗p < 0.01 vs. vehicle + saline group.
multiple comparisons showed that morphine-treated mice
presented a significant increase in distance traveled compared
with the control mice (vehicle + morphine, n = 9 vs. vehicle +
saline, n = 9, p = 0.011). MDL 11,939 treatment prevented the
morphine-induced increase in locomotor activity (MDL 11,939+
morphine, n= 9 vs. vehicle+ saline, p= 1.000). MDL 11,939 did
not alter the distance traveled when compared with the vehicle
(MDL11,939+ saline, n= 9 vs. vehicle+ saline, p= 1.000). The
distance traveled at each 5-min time bin was further compared
with a one-way ANOVA followed by post hoc Bonferroni multiple
comparisons. Morphine administration increased the distance
mice traveled in the task between 20 and 60 min compared
with the vehicle (vehicle + morphine vs. vehicle + saline).
A two-way repeated measures ANOVA on immobility measured
in 5-min bins revealed a significant main effect of treatment
[F(3,32) = 6.578, p = 0.001] and a significant main effect of
treatment× time bin interaction [F(33,352)= 1.511, p= 0.039],
but no effect of the time bin [F(11,352) = 0.925, p = 0.516]
(Figure 1B). Post hoc Bonferroni multiple comparisons showed
that morphine-treated mice presented a significant decrease in
immobility compared with the control mice (vehicle+morphine
vs. vehicle + saline, p = 0.047). MDL 11,939 pretreatment
prevented the morphine-induced decrease in immobility (MDL
11,939 +morphine vs. vehicle + saline, p = 1.000). MDL 11,939
did not alter the distance traveled compared with the vehicle
(MDL 11,939 + saline vs. vehicle + saline, p = 0.803). The
immobility was further compared at each 5-min time bin using
a one-way ANOVA followed by post hoc Bonferroni multiple
comparisons. Morphine administration resulted in a decrease in
immobility from 25 to 45 min compared with the control mice
(vehicle+morphine vs. vehicle+ saline). Moreover, MDL 11,939
at 0.125 and 0.25 mg/kg did not affect the morphine-induced
increase in locomotor activity (Supplementary Figure S2).
MDL 11,939 Suppresses the Expression
of Morphine-Induced Behavioral
Sensitization
MDL 11,939 (0.5 mg/kg, i.p.) was administered 20 min before
the morphine (10 mg/kg, s.c.) challenge on day 9 in the
morphine behavioral sensitization model. MDL 11,939 altered
the morphine-induced behavioral sensitization. A two-way
repeated measures ANOVA on distance traveled measured in
5-min time bins revealed a significant main effect of treatment
[F(1,18) = 9.81, p = 0.006], a significant effect of time bin
[F(11,198) = 19.94, p < 0.001] and a significant main effect of
treatment × time bin interaction [F(11,198) = 4.99, p < 0.000]
(Figure 2A). The distance traveled was further compared at
each 5-min bin with an independent samples Student’s t-test.
MDL 11,939 administration (n = 10) suppressed morphine-
induced increase in distance traveled during the task from 15 to
55 min compared with the vehicle (n = 10). A two-way repeated
measures ANOVA on immobility revealed a significant main
effect of treatment [F(1,18) = 4.89, p = 0.04] and a significant
main effect of time bin [F(11,198) = 7.96, p < 0.001], but no
effect of the treatment × time bin interaction [F(11,198) = 1.51,
p = 0.131] (Figure 2B). The immobility at each time point
was compared with an independent samples Student’s t-test.
MDL 11,939 administration suppressed the morphine-induced
decrease in immobility from 15 to 45 min compared with vehicle
+morphine treatment.
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FIGURE 2 | MDL 11,939 suppresses the expression of morphine-induced behavioral sensitization. MDL 11,939 (0.5 mg/kg, i.p.) was administered 20 min
before the morphine (10 mg/kg, s.c.) challenge on day 9 in morphine behavioral sensitization model. (A) MDL 11,939 treatment suppressed morphine-induced
increase in distance traveled measured in 5-min time bins compared to the vehicle (p = 0.006). (B) MDL 11,939 treatment prevented morphine-induced decrease in
immobility measured in 5-min time bins compared with the vehicle (p = 0.04). Data are expressed as mean ± S.E.M; n = 10 in each group; ∗p < 0.05, ∗∗p < 0.01
vs. vehicle + morphine group.
FIGURE 3 | MDL 11,939 suppresses naloxone-precipitated withdrawal in morphine-dependent mice. MDL 11,939 (0.5 mg/kg, i.p.) was administered
15 min before the naloxone (5.0 mg/kg, s.c.) challenge to precipitate morphine withdrawal. (A) MDL 11,939 treatment suppressed naloxone-precipitated increase in
distance traveled measured in 5-min time bin (p = 0.004). (B) MDL 11,939 treatment suppressed naloxone-precipitated decrease in immobility measured in 5-min
time bin (p = 0.001). Data are expressed as mean ± S.E.M; n = 10 in each group; ∗p < 0.05, ∗∗p < 0.01 vs. vehicle + naloxone group.
MDL 11,939 Suppresses
Naloxone-Precipitated Withdrawal in
Morphine-Dependent Mice
MDL 11,939 (0.5 mg/kg, i.p.) was administered 15 min
prior to the naloxone (5.0 mg/kg, s.c.) challenge in order to
precipitate morphine withdrawal. MDL 11,939 altered naloxone-
precipitated withdrawal in morphine-treated mice. A two-way
repeated measures ANOVA on distance traveled measured in
5-min time bin revealed a significant main effect of treatment
[F(1,18) = 10.63, p = 0.004], a significant main effect of time
bin [F(11,198) = 6.53, p < 0.001] and a significant effect of
treatment × time bin interaction [F(11,198) = 2.20, p = 0.016]
(Figure 3A). The distance traveled was further compared at
each 5-min time bin using an independent samples Student’s
t-test. MDL 11,939 (n = 10) suppressed morphine-induced
increases in distance traveled from 15 to 50 min compared
with the vehicle + morphine group mice (n = 10). A two-
way repeated measures ANOVA on immobility measured in
5-min time bin revealed a significant main effect of treatment
[F(1,18) = 16.79, p = 0.001], a significant main effect of time
bin [F(11,198) = 5.51, p < 0.001], and a significant effect of
treatment × time bin interaction [F(11,198) = 3.46, p < 0.001]
(Figure 3B). The immobility was further compared at each 5-
min time bin with an independent samples Student’s t-test.
Systemic MDL 11,939 suppressed morphine-induced decreases
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in immobility from 15 to 50 min compared with the vehicle
+ morphine group. Moreover, MDL 11,939 administration
suppressed jumping behavior in morphine withdrawal mice
(Table 1).
Chronic Morphine Treatment Is
Associated with an Increase in 5-HT2AR
Protein Level and a Decrease in ERK
Phosphorylation in PFC and
Hippocampus
Mice received increasing doses of morphine over 7 days to
develop morphine dependence, and brain tissue was harvested
2.5 h after last morphine injection. 5-HT2AR, pERK and ERK
levels in PFC and hippocampus were detected using WB assay.
Chronic morphine treatment was associated with an increase
in 5-HT2CR expression [t(4) = 3.75, p = 0.02], and a decrease
in the ratio of pERK/ERK in PFC [t(6) = 5.43, p = 0.001]
(Figure 4) compared with the vehicle treatment. Similarly,
morphine treatment induced a trend of increase in 5-HT2AR
expression and a trend of decrease in ERK phosphorylation in
hippocampus.
DISCUSSION
The present studies examined the modulation of 5-HT2ARs on
morphine-induced increases in locomotor activity, behavioral
sensitization, and withdrawal in mice. Our results indicated
that blockade of 5-HT2ARs with MDL 11,939 suppressed
morphine-induced hyperactivity, behavioral sensitization,
and naloxone-precipitated withdrawal symptoms. Moreover,
repeated morphine treatment was associated with an increase in
5-HT2AR expression and a decrease in ERK phosphorylation in
PFC. Together, these results by the first time demonstrates that
5-HT2ARs modulate morphine dependence and pharmacological
blockade of 5-HT2ARs may be a novel strategy for the treatment
of opioid use disorders.
Our results confirmed that a systemic blockade of 5-HT2ARs
suppressed morphine-induced increase in locomotor activity.
Previous studies revealed that acute and chronic morphine
treatments increased locomotor activity, DA and 5-HT release,
which could be prevented by the 5-HT2AR antagonist SR46349B
pretreatment (Tao and Auerbach, 1995; Auclair et al., 2004).
Morphine suppress the neuronal firing of VTA GABAergic
interneurons via µ-opioid receptors, leading to a disinhibition
of VTA dopaminergic neurons and an increase in DA release
(Johnson and North, 1992). It suggests that morphine induces
locomotor hyperactivity by suppressing GABAergic neurons
and, subsequently, the resultant boosting of dopaminergic
neurotransmission (Iwamoto, 1981). A subpopulation of VTA
dopaminergic neurons expresses 5-HT2AR (Doherty and Pickel,
2000). Local infusion of 5-HT2AR antagonist M100907 in VTA
prevented cocaine induced hyperactivity (McMahon et al., 2001).
These indicate that MDL 11,939 attenuates the 5-HT2AR-
mediated excitatory effect on VTA dopaminergic neurons, and
suppresses morphine-induced locomotor hyperactivity.
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FIGURE 4 | Chronic morphine treatment is associated with an increase in 5-HT2AR expression and a decrease in ERK phosphorylation in the PFC
and hippocampus. Mice received increasing doses of morphine for 7 days to develop morphine dependence, and brain was harvested 2.5 h after last injection.
(A) Chronic morphine treatment was associated with an increase in 5-HT2AR expression in PFC (p = 0.02), and (C) a decrease in the ratio of pERK/ERK in PFC
(p = 0.001). The hippocampus also presented a trend of an increase in 5-HT2AR expression (B) and a decrease in ERK phosphorylation (D). Data are expressed as
mean ± S.E.M; n = 10 in each group; ∗p < 0.05, ∗∗p < 0.01 vs. saline group.
Behavioral sensitization is developed by drug-induced
immediate molecular and/or cellular changes in the VTA. DA
neurotransmission within the NAc plays a vital role in the
expression of behavioral sensitization (Kalivas and Stewart,
1991). Our results revealed that blockade of 5-HT2ARs inhibited
the expression of behavioral sensitization in morphine-treated
mice. It suggests that MDL 11,939 attenuates the 5-HT2AR-
mediated excitatory effect on NAc dopaminergic neurons,
and suppresses morphine-induced behavioral sensitivity.
Consistently, 5-HT2AR antagonist SR46349B prevents the
development and expression of morphine-induced sensitization
(Auclair et al., 2004).
Physical dependence and withdrawal symptoms are
characteristics of morphine addiction. The phenotypes of
morphine withdrawal in rodents include jumping, ptosis,
diarrhea, wet dog shakes, and motivational dysfunction (Zhang
et al., 2016b). It is assumed that locus coeruleus (LC) modulates
jumping, rearing, and locomotor activity, periaqueductal gray
matter regulates rearing and locomotor activity, and anterior
preoptic hypothalamus and nucleus raphe magnus controls wet
dog shake (Koob et al., 1992). Morphine exposure suppresses
LC neuronal activity, while abrupt morphine termination
disinhibits LC neurons and increase LC neuronal firing, leading
to withdrawal symptom precipitation (Taylor et al., 1988).
Blockade of 5-HT2ARs attenuated the neuronal excitation critical
for precipitating morphine withdrawal. The mechanisms behind
need further investigation.
Results from WB assay revealed that chronic morphine
treatment increased 5-HT2AR protein expression and decreased
in ERK phosphorylation in PFC. The PFC is a critical brain
region associated with drug addictive behaviors. For example,
Chemical lesions of the mPFC disrupt the development of
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cocaine and amphetamine-induced sensitization (Wolf et al.,
1995), suggesting that increase in 5-HT2AR expression is a
critical neuroadaptative component resulted from morphine
exposure. The signaling and functional significances of the
morphine-induced 5-HT2AR protein overexpression remains
illusive. Identify the subcellular distribution of 5-HT2ARs,
receptor signaling and functional characteristics will be
necessary to understand the protein change. Interestingly,
ERK phosphorylation was decreased in both the PFC and
hippocampus to chronic morphine treatment. Although
activation of 5-HT2ARs can increase pERK1/2 formation (Millan
et al., 2008; Masson et al., 2012), ERK phosphorylation is
regulated by multiple cellular signals, and the inconsistency
between 5-HT2AR expression and pERK accumulation may be
attributed to other factors.
MDL 11,939 is a potent and selective 5-HT2AR antagonist.
Glemanserin (MDL 11,939) was clinically investigated for the
treatment of generalized anxiety disorder due to its efficacy,
safety, as well as the probability to cross the blood-brain
barrier (Sramek et al., 1995). In the present study, we
used MDL 11,939 as a tool to explore the neurobiological
mechanism of morphine-induced behavioral change. Based on
our data, MDL 11,939 may serve as a medical treatment for
morphine use disorders in human. 5-HT2ARs are expressed
predominately in nociceptive sensory neurons in lumbar
dorsal root ganglia and participate in pain regulation (Van
Steenwinckel et al., 2009). MDL 11,939 has been show
to suppress 2′,3′-dideoxycytidine-induced neuropathic pain
in rats; 5-HT2AR knock-out mice did not develop 2′,3′-
dideoxycytidine-induced neuropathy (Van Steenwinckel et al.,
2008). We previously demonstrated that MDL 11,939 could
suppress acetic acid-induced acute pain, incision pain and
sciatic nerve ligation neuropathic pain in mice (unpublished).
The influence of MDL 11,939 on anxiety and pain may
participate in its effects on morphine-induced behavioral
changes.
Drug exposure is associated with oxidative stress in the
brain (Guzman et al., 2006; Abdel-Zaher et al., 2013; Schiavone
et al., 2016). Chronic morphine treatment induces a progressive
increase in brain glutamate and oxidant malondialdehyde (MDA)
levels and a progressive decrease in brain non-enzymatic
antioxidant, intracellular glutathione (GSH) levels and enzymatic
antioxidant, GSH-Px activity (Abdel-Zaher et al., 2013). Nitric
oxide synthase inhibitors, phospholipase A2 inhibitors and
free radical scavengers attenuate the expression of naloxone-
precipitated withdrawal syndrome in morphine-dependent mice
(Mori et al., 2007; Abdel-Zaher et al., 2013). The Nicotinamide
Adenine Dinucleotide Phosphate (NADPH) oxidase NOX
enzyme is a major contributor of oxidative damage in the
CNS, being involved in a variety of brain disorders. Mice
with NOX1 mutation present an augment of morphine-induced
analgesia and an inhibition of tolerance (Ibi et al., 2011).
Serotonergic neurotransmission may also participate in the
morphine-induced oxidative stress. Morphine increases 5-HT
release and oxidative metabolism (Enrico et al., 1998). The 5-HT
metabolite melatonin can also scavenge free radicals and abort
oxidative stress present in damaged tissue (Ebadi et al., 1998).
Glutamate can induce oxidative stress (Atlante et al., 2001). We
previously demonstrated that activation of 5-HT2AR enhances
glutamate release (Zhang et al., 2016a). It is postulated that
MDL 11,939 attenuates oxidative stress by blockade of 5-HT2ARs
and subsequent glutamate release. It is interesting to further
investigate serotonergic neurotransmission in morphine-induced
oxidative stress and addiction.
The present studies revealed that blockade of 5-HT2AR
suppresses the expression of morphine-induced behavioral
sensitization and ameliorates naloxone-precipitated withdrawal
symptoms. In addition, chronic morphine exposure increase 5-
HT2AR protein level within the PFC. 5-HT2AR may be a potential
target for the treatment of morphine use disorders.
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